EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer

Marieke Heinrich iD, Elias Blickle, Philipp E Hartrampf, Natalie Hasenauer, Aleksander Kosmala, Alexander Kerscher, Nicolas Schlegel, Frederik A Verburg, Andreas K Buck, Kerstin Michalski

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07187-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Marieke Heinrich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany. heinrich_m4@ukw.de. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes, Single Photon Emission Computed Tomography Computed Tomography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg, Universitätsklinikum Würzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study is to investigate the impact of lymph node metastases (LNM) detected on cervical 131 I single photon emission computed tomography/computed tomography (SPECT/CT) after the first radioiodine therapy (RAI) on complete response (CR) and progression-free survival (PFS) in patients with differentiated thyroid cancer (DTC).

Methods

This retrospective study included 942 DTC patients who underwent cervical 131 I SPECT/CT after their first RAI. LNM were categorized based on CT (enlarged ≥ 1 cm, small < 1 cm) and 131 I uptake. CR and PFS were analysed using Kaplan–Meier curves and Cox regression.

Results

Patients with no LNM had a shorter median time to CR (9.4 months) than those with LNM (44 months, HR 2.2; p < 0.01) and a lower risk of progression (median PFS not reached, HR 0.46; p < 0.01). Among patients with LNM, those with enlarged 131 I negative LNM had the longest time to CR (24 months, HR 0.36; p < 0.01). Patients with small LNM had a PFS similar to patients without LNM (median PFS not reached, HR 1.22; p = 0.54). Reoperation after first RAI (13.5 months) led to earlier CR than second RAI (median not reached) in patients with enlarged LNM. For small LNM, second RAI was associated with longer PFS than reoperation (38.4 months vs. not reached, HR 4.0; p = 0.02).

Conclusion

Patients without LNM on post-therapy 131 I SPECT/CT have better chances for early CR and longer PFS. Patients with LNM benefit from early reoperations but treatment strategies should be tailored based on LNM characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsIodine RadioisotopesSingle Photon Emission Computed Tomography Computed TomographyHumansFemaleMaleMiddle AgedAdultRetrospective StudiesAgedPrognosisLymphatic MetastasisYoung AdultAdolescentAged, 80 and over

Stichwörter der Autor:innen

131I SPECT/CTComplete responseLymph node metastasesProgression-free survivalRadioiodine therapyReoperation

Substanzen

Iodine RadioisotopesIodine-131

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany. heinrich_m4@ukw.de.
  • Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.
  • Comprehensive Cancer Centre Mainfranken, University Hospital Wuerzburg, Wuerzburg, Germany.
  • Department of Surgery I, University Hospital Wuerzburg, Wuerzburg, Germany.
  • Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, University Rotterdam, Rotterdam, Netherlands.

ORCID-Profile: Marieke Heinrich

Förderung

  • Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
  • Universitätsklinikum Würzburg

Zitieren

APA

Heinrich, M., Blickle, E., Hartrampf, P. E., Hasenauer, N., Kosmala, A., Kerscher, A., Schlegel, N., Verburg, F. A., Buck, A. K., & Michalski, K. (2025). 131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07187-1

Vancouver

Heinrich M, Blickle E, Hartrampf PE, Hasenauer N, Kosmala A, Kerscher A, et al. 131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07187-1

BibTeX
@article{Heinrich2025,
  author = {Heinrich, Marieke and Blickle, Elias and Hartrampf, Philipp E and Hasenauer, Natalie and Kosmala, Aleksander and Kerscher, Alexander and Schlegel, Nicolas and Verburg, Frederik A and Buck, Andreas K and Michalski, Kerstin},
  title = {131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07187-1}
}
Kostenlos starten →